#asco23 — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #asco23, aggregated by home.social.
-
In ER positive and HER2 negative #BreastCancer detection of circulating tumor DNA (ct DNA) following neoadjuvant chemotherapy and surgery, is associated with a very high risk of early relapse. This suggests also limited efficacy of adjuvant endocrine therapy. Studies of clinical imaging and of experimental therapy are warranted in this patient population, especially in patients who fail to ‘clear’ ctDNA.
#ASCO23 Presentation slides are available now: https://www.gbg.de/de/newsroom/meldungen/2023-05-asco.php -
In patients with triple negative #BreastCancer RNA expression levels from peripheral immune cells could serve as a minimal-invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events. RNA expression levels could therefore enable differentiation between patients who might benefit from neoadjuvant immune checkpoint therapy compared to standard therapies. #ASCO23
Presentation slides are available now: https://www.gbg.de/de/newsroom/meldungen/2023-05-asco.php -
AstraZeneca study points to new uses for targeted cancer drug Enhertu— Novo Nordisk enters talks to buy device maker Biocorp --J&J sees trial data supporting earlier CAR-T use in multiple myeloma -- See more on our front page news http://bit.ly/w28kSd #asco #asco23 #asco2023 #astrazeneca #enhertu #cancer #mergersandacquisitions #novonordisk #cart #jnj #multiplemyeloma #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
#ICYMI at yesterday’s #ASCO23 Opening Session, Dr. Eric Winer described the theme of the meeting, which is “Partnering with Patients: The Cornerstone of Clinical Cancer and Research” and shared his own personal health journey.
He also presented lessons related to the importance of partnerships between clinicians and patients:
1) Relationship with health care team is paramount
2) Science matters
3) We all face challenges
4) Responses to illness vary across individuals
5) Stigma can be crushing -
#ICYMI at yesterday’s #ASCO23 Opening Session, Dr. Eric Winer described the theme of the meeting, which is “Partnering with Patients: The Cornerstone of Clinical Cancer and Research” and shared his own personal health journey.
He also presented lessons related to the importance of partnerships between clinicians and patients:
1) Relationship with health care team is paramount
2) Science matters
3) We all face challenges
4) Responses to illness vary across individuals
5) Stigma can be crushing -
#ICYMI at yesterday’s #ASCO23 Opening Session, Dr. Eric Winer described the theme of the meeting, which is “Partnering with Patients: The Cornerstone of Clinical Cancer and Research” and shared his own personal health journey.
He also presented lessons related to the importance of partnerships between clinicians and patients:
1) Relationship with health care team is paramount
2) Science matters
3) We all face challenges
4) Responses to illness vary across individuals
5) Stigma can be crushing -
ASCO 2023 news drops ahead of June meeting: Merck, BMS, Regeneron, and more — Noom to offer prescriptions for weight-loss drugs --ASCO puts spotlight on advancing antibody-drug conjugate pipeline -- See more on our front page news http://bit.ly/w28kSd #asco2023 #asco23 #merck #regeneron #bristolmyerssquibb #antibodydrugconjugate #noom #wegovy #weightloss #ozempic #novonordisk #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
🎉While we were on hiatus, we received notification of our #ASCO23 abstract acceptance for discussion!!
We’re thrilled to bring more awareness of the impact #TumorBoardTuesday discussions continue to have on knowledge of novel therapies and toxicities in solid tumor oncology!🙏🏼
-
🎉While we were on hiatus, we received notification of our #ASCO23 abstract acceptance for discussion!!
We’re thrilled to bring more awareness of the impact #TumorBoardTuesday discussions continue to have on knowledge of novel therapies and toxicities in solid tumor oncology!🙏🏼
-
💙We hear there's an #ASCO23 deadline tonight, but there's always time for #TumorBoardTuesday!
💙1 hour countdown!!
💙@arkhaki @glovedoc take us through early progression of #UrothelialCancer
💙Brew coffee & prepare your 🧠with these #CME👇🏽See you soon!
---
RT @TumorBoardTues
#PreTest Q1️⃣ #TumorBoardTuesday
Free #CME🔗http://integrityce.com/tbt👉Before @arkhaki & @glovedoc🗣️mgmt of #Urothelialcancer, test your 🧠with these❓s
🤔What …
https://twitter.com/TumorBoardTues/status/1625554522838863883 -
💙We hear there's an #ASCO23 deadline tonight, but there's always time for #TumorBoardTuesday!
💙1 hour countdown!!
💙@arkhaki @glovedoc take us through early progression of #UrothelialCancer
💙Brew coffee & prepare your 🧠with these #CME👇🏽See you soon!
---
RT @TumorBoardTues
#PreTest Q1️⃣ #TumorBoardTuesday
Free #CME🔗http://integrityce.com/tbt👉Before @arkhaki & @glovedoc🗣️mgmt of #Urothelialcancer, test your 🧠with these❓s
🤔What …
https://twitter.com/TumorBoardTues/status/1625554522838863883